Mithra Pharmaceuticals gets boost from positive Estetrol data

Mithra Pharmaceuticals SA

12/10/2022 09:09

** Shares Mithra Pharmaceuticals  MITRA.BR  rise around 2%
after the Belgian biotech group published positive pre-clinical
data on hormone Estetrol's (E4) efficacy in wound healing and
said it targets a clinical launch in H2 2023  urn:newsml:reuters.com:*:nFWN31D00G
    ** Portzamparc ("buy") says this is good news for Mithra
that has always studied wound healing alongside women's health
    ** "The road ahead in wound healing," KBC Securities ("buy")
says, as the news reconfirms Mithra's potential avenues outside
of women's health
    ** "We believe Mithra is now taking further steps in
determining its mid to long-term future," KBC adds, pointing to
drug Estelle being marketed by commercial partners and Donesta's
clinical trials
    ** ING ("buy") says the news is positive for the market
sentiment as it confirms E4's differentiated profile compared to
other oestrogens currently on the market, adding it had not
modelled any potential revenues for this indication
    ** "We however expect the impact on our valuation model to
be somewhat limited, given the low probability of success we
would attach to a programme that did not yield any clinical
data," ING says
    ** Including Wednesday's rise, the stock has dropped 68% YTD
 (Reporting by Elena Vardon)
 ((elena.vardon@tr.com))